Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(6):700–704. doi: 10.1038/bjc.1997.449

Idoxifene is equipotent to tamoxifen in inhibiting mammary carcinogenesis but forms lower levels of hepatic DNA adducts.

P Pace 1, M Jarman 1, D Phillips 1, A Hewer 1, J Bliss 1, R C Coombes 1
PMCID: PMC2228034  PMID: 9310233

Abstract

Tamoxifen is an effective agent preventing mammary carcinogenesis in rats but causing liver tumours. Idoxifene is a more potent antioestrogen and is effective in patients with advanced breast cancer. We therefore compared the effects of idoxifene with tamoxifen on mammary carcinogenesis and hepatic DNA adduct formation. To do this, we undertook a study designed to compare tamoxifen with idoxifene as a chemopreventive agent in rats inoculated with N-methylnitrosourea (MNU) and also measured hepatic adduct formation. We examined the time to mammary tumour development in 272 female Ludwig/Wistar/Olac rats treated with MNU followed by tamoxifen (5 mg kg(-1)), equimolar idoxifene or vehicle three times a week for up to 24 weeks. To determine duration of effect, a second study was carried out whereby all of the 129 animals surviving at the end of treatment were entered into a surveillance programme for 27 weeks after the end of the administration period. Hepatic DNA adduct formation was examined by 32P-postlabelling in a group of rats after 24 weeks' treatment. In the first study, both idoxifene and tamoxifen were effective in preventing tumour growth as only 2 out of 21 (10%) MNU and vehicle-treated animals were alive and tumour free after 24 weeks compared with 13 out of 22 (59%) animals receiving MNU followed by idoxifene or tamoxifen (P < 0.001). The second study showed that, in both idoxifene- and tamoxifen-treated animals, a progressive regrowth of tumours occurred after cessation of therapy, as by the end of the observation period only four idoxifene-treated animals and one tamoxifen-treated animal were free from disease. In the subset of animals tested, tamoxifen-treated animals had approximately 100 times higher levels of DNA hepatic adducts than idoxifene-treated animals. Adducts were not seen in the control group. These results indicate that idoxifene is as effective a chemopreventive agent as tamoxifen in the rat while causing only very low levels of DNA adducts in liver tissue and suggest that idoxifene may be a well-tolerated chemopreventive agent in women who are at increased risk of breast cancer.

Full text

PDF
700

Images in this article

703Figure 4
on p.703

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bruning P. F. Droloxifene, a new anti-oestrogen in postmenopausal advanced breast cancer: preliminary results of a double-blind dose-finding phase II trial. Eur J Cancer. 1992;28A(8-9):1404–1407. doi: 10.1016/0959-8049(92)90530-f. [DOI] [PubMed] [Google Scholar]
  2. Chander S. K., McCague R., Luqmani Y., Newton C., Dowsett M., Jarman M., Coombes R. C. Pyrrolidino-4-iodotamoxifen and 4-iodotamoxifen, new analogues of the antiestrogen tamoxifen for the treatment of breast cancer. Cancer Res. 1991 Nov 1;51(21):5851–5858. [PubMed] [Google Scholar]
  3. Coombes R. C., Haynes B. P., Dowsett M., Quigley M., English J., Judson I. R., Griggs L. J., Potter G. A., McCague R., Jarman M. Idoxifene: report of a phase I study in patients with metastatic breast cancer. Cancer Res. 1995 Mar 1;55(5):1070–1074. [PubMed] [Google Scholar]
  4. Gupta R. C. Nonrandom binding of the carcinogen N-hydroxy-2-acetylaminofluorene to repetitive sequences of rat liver DNA in vivo. Proc Natl Acad Sci U S A. 1984 Nov;81(22):6943–6947. doi: 10.1073/pnas.81.22.6943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Jordan V. C. Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol. 1993 Oct;110(2):507–517. doi: 10.1111/j.1476-5381.1993.tb13840.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. McCague R., Leclercq G., Legros N., Goodman J., Blackburn G. M., Jarman M., Foster A. B. Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. J Med Chem. 1989 Dec;32(12):2527–2533. doi: 10.1021/jm00132a006. [DOI] [PubMed] [Google Scholar]
  7. McCague R., Parr I. B., Leclercq G., Leung O. T., Jarman M. Metabolism of tamoxifen by isolated rat hepatocytes. Identification of the glucuronide of 4-hydroxytamoxifen. Biochem Pharmacol. 1990 May 1;39(9):1459–1465. doi: 10.1016/0006-2952(90)90427-m. [DOI] [PubMed] [Google Scholar]
  8. Phillips D. H., Carmichael P. L., Hewer A., Cole K. J., Poon G. K. alpha-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res. 1994 Nov 1;54(21):5518–5522. [PubMed] [Google Scholar]
  9. Phillips D. H., Potter G. A., Horton M. N., Hewer A., Crofton-Sleigh C., Jarman M., Venitt S. Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis. 1994 Aug;15(8):1487–1492. doi: 10.1093/carcin/15.8.1487. [DOI] [PubMed] [Google Scholar]
  10. Poon G. K., Walter B., Lønning P. E., Horton M. N., McCague R. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab Dispos. 1995 Mar;23(3):377–382. [PubMed] [Google Scholar]
  11. Powles T. J., Hardy J. R., Ashley S. E., Farrington G. M., Cosgrove D., Davey J. B., Dowsett M., McKinna J. A., Nash A. G., Sinnett H. D. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer. 1989 Jul;60(1):126–131. doi: 10.1038/bjc.1989.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Powles T. J., Tillyer C. R., Jones A. L., Ashley S. E., Treleaven J., Davey J. B., McKinna J. A. Prevention of breast cancer with tamoxifen--an update on the Royal Marsden Hospital pilot programme. Eur J Cancer. 1990;26(6):680–684. doi: 10.1016/0277-5379(90)90116-b. [DOI] [PubMed] [Google Scholar]
  13. Scholl S. M., Huff K. K., Lippman M. E. Antiestrogenic effects of LY 117018 in MCF-7 cells. Endocrinology. 1983 Aug;113(2):611–617. doi: 10.1210/endo-113-2-611. [DOI] [PubMed] [Google Scholar]
  14. Seoud M. A., Johnson J., Weed J. C., Jr Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol. 1993 Aug;82(2):165–169. [PubMed] [Google Scholar]
  15. Vogel C. L., Shemano I., Schoenfelder J., Gams R. A., Green M. R. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J Clin Oncol. 1993 Feb;11(2):345–350. doi: 10.1200/JCO.1993.11.2.345. [DOI] [PubMed] [Google Scholar]
  16. Wakeling A. E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991 Aug 1;51(15):3867–3873. [PubMed] [Google Scholar]
  17. White I. N., de Matteis F., Davies A., Smith L. L., Crofton-Sleigh C., Venitt S., Hewer A., Phillips D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis. 1992 Dec;13(12):2197–2203. doi: 10.1093/carcin/13.12.2197. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES